Top Tweets for #KIdneyCancer
🔔 FDA approves belzutifan + lenvatinib for adults with advanced RCC with a clear cell component after prior PD-1/PD-L1 therapy.
📅 September 24, 2026
A new combination option in the post-immunotherapy setting.
#KidneyCancer #RCC #GUOnc
@OncoAlert @ONCOassist @bildiginbenim
FDA approves Merck-Eisai drug combination for advanced kidney cancer
https://t.co/tb8dOmueKp
#USFDA #Merck #Eisai #drug #kidneycancer
#EuropeanSocietyforMedicalOncology
#WELIREG #belzutifan #LENVIMA #lenvatinib
@indpharmapost
Did you see the latest report on #KidneyCancer from @NKCA_NATCAN @NATCAN_news @HQIP❓
This audit of care received by people diagnosed with kidney cancer examines diagnosis, surgery and systemic treatment.
�� https://t.co/7DUk2zUzlR
#ClinicalAudit #CancerAudit @kidneycanceruk
Today marks an important milestone in #KidneyCancer. Together with @Merck, we're pleased to share news of a U.S. FDA approval for certain previously treated patients with advanced renal cell carcinoma (#RCC). Learn more: https://t.co/CDzxFwW24q
Kidney Cancer: Kidney Mein Tumor Kaise Pehchana Jata Hai?
Expert Urological Care
Dr. Devendra Kumar Babbar
Dr. Vipin Sisodia
Appointments:
+91 9990509314 | +91 9843022153
🌐 https://t.co/A4lIegiRix
-
#KidneyCancer #KidneyTumor #KidneyHealth #KidneyCancerAwareness #Urology
📢 FDA Approval Alert: The #FDA has approved belzutifan plus lenvatinib for advanced clear cell #RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.
Read more: https://t.co/CavjghV6pD
#KidneyCancer #ccRCC #Oncology #CancerTreatment
⚡️ FDA approves belzutifan + lenvatinib for advanced ccRCC after PD-1/PD-L1 inhibitor therapy.
Based on LITESPARK-011: median PFS 14.6 vs 10.6 months (HR 0.74) vs cabozantinib. OS not significantly different at final analysis.
#KidneyCancer @OncoAlert
https://t.co/7UMHxEr1C1
#FDA approval after PD-1/PD-L1 therapy in advanced clear-cell RCC: #belzutifan + #lenvatinib.
#KidneyCancer #Oncology
Terrific talk by @TylerRobinMD @CUSystem at #BKCA26 hosted by @TomJayram & #DrNealShore @CURCMB. Eloquent summary of data from @ChadTangMD, @_ShankarSiva & others who have made radiation a reality for #kidneycancer in a variety of settings.
FDA approval (Sept 24): belzutifan (Welireg) + lenvatinib (Lenvima) for advanced clear cell RCC after a PD-1/PD-L1 inhibitor. In LITESPARK-011 it beat cabozantinib on PFS head-to-head. But what about overall survival?
#KidneyCancer #Oncology
https://t.co/604S6dwtr7
IKCC Global Patient Survey、前回は日本からの登録数が世界2位でした。決して順番を競ってるわけではないですが、現在のように治療開発がglobalで進んでいる中で、日本の患者さんの声を世界に届けるという意義は深いと思います。@IKCCorg #KidneyCancer
📢 Today, on World Cancer Research Day, the 5th IKCC Global Patient Survey on Kidney Cancer is now open!
People who have been diagnosed with kidney cancer and carers are invited to share patient experiences and insights in the online survey:
https://t.co/DGgeMhhuRg
FDA 🇺🇸 News: LITESPARK-011 Update in #kidneyCancer
Source: FDA
https://t.co/4UrzMFQDGV
On September 24, 2026, the FDA🇺🇸 approved belzutifan plus lenvatinib for adults with advanced renal cell carcinoma containing a clear cell component after PD-1/PD-L1 inhibitor treatment. In the LITESPARK-011 trial, the combination significantly improved progression-free survival and objective response rate versus cabozantinib, while overall survival was not statistically significant.
➡️ Median PFS was 14.6 versus 10.6 months, with response rates of 53% versus 40%. ➡️ Key safety concerns include anemia, hypoxia, cardiac dysfunction, hypertension, and embryo-fetal toxicity.
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @AlbigesL, @cdanicas, @amerseburger, @sonpavde, @DrDanielHeng, @declangmurphy, @seanmmcbride, @HHammersMD, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @scocmem, @ravikanesvaran, @AmandaNizamMD, @drenriquegrande, @BraunMDPhD, @EfstathiouEleni, @nataliagandur, @crisbergerot, @realbowtiedoc, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrMirallas
Today on World Cancer Research Day, KidneyCAN and @IKCCorg have launched the 2026-2027 Global Patient Survey on Kidney Cancer! All #kidneycancer patients, carers, and survivors are invited to share their experiences and insights in the online survey.
https://t.co/P4t9DfkP6c
#AcceleratingCures
The FDA approved the combination of belzutifan (Welireg) and lenvatinib (Lenvima) for adults with advanced clear cell RCC whose disease progressed on or after prior PD-1 or PD-L1 checkpoint inhibitor therapy: https://t.co/9fU40iIcHU #KidneyCancer #FDAApproval #Welireg #Lenvima
At the Bladder & Kidney Cancer Academy (hosted by #DrNealShore @CU@CURCMB & @TomJayram). Beautiful talk on #kidneycancer imaging from @KidneyCancerDoc who led the #ZIRCON study, hopefully leading to wide availability of CAIX imaging for our pts. Beyond this, great insights on use of sestamibi & #PSMA imaging.
Great news for #KidneyCancer pts
I hope it will be available in Ireland soon
@TUH_Tallaght was among highest 🔝recruiting sites globally
We know it’s very well tolerated in Irish cohort
🌅Life saving for many pts
@UCANIRELAND
@ipha
@hseNCCP
New @FDA approval in advanced kidney cancer: belzutifan + lenvatinib after prior PD-1/PD-L1 therapy.
Another meaningful option after IO.
@KidneyCancer @kidneycan @IKCCorg @OncoAlert @OpenMedicineHQ
Every advancement in cancer care begins with research.
On #WorldCancerResearchDay, we recognize the scientists, clinicians, patients, advocates, and supporters whose contributions help turn questions into discoveries.
In #KidneyCancer, research has transformed our understanding of the disease and continues to open new possibilities for diagnosis, treatment, and care. But there is still more to learn and more progress to make.
#AcceleratingCures
FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcino...
https://t.co/ohjQprnQnI
https://t.co/i7Y2ia3zT2
#LARVOL #CancerResearch #OncologyInsights #RenalCellCarcinoma #KidneyCancer #Belzutifan @DrRishabhOnco @DrChoueiri @tompowles1 @SuyogCancer
The 5th @IKCCorg Global Patient Survey on #KidneyCancer is now open!
Your lived experience matters, please share your voice take the 15minute survey and help shape the future of kidney cancer care.
For info and to take the survey:
https://t.co/D8cGd3iuJd
#GlobalPatientSurvey
First in-person meeting of the #pRCCTREAT consortium at @IIBmCSICUAM , Madrid!
Two days of great discussions, collaboration and planning to advance research in papillary renal cell carcinoma. Excited for what's ahead! 🔬 #KidneyCancer #personalisedmedicine
Last Seen Hashtags on Sotwe
แลกรูปควย
Seen from Thailand
highheeltrample
Seen from Turkey
jeffxfox
Seen from France
nicoledoshi bbc
Seen from Indonesia
incestkink mother
Seen from Turkey
ATTC
Seen from United States
eskişehir travesti
Seen from Turkey
Teenager
Seen from Belgium
阿黑颜
Seen from United States
ควยเณร
Seen from Thailand
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers